Evidence map›Paper›PMID 25548107›Full record

Trial reportThe international journal of neuropsychopharmacology2014

Cannabinoid modulation of amygdala subregion functional connectivity to social signals of threat.

Stephanie M Gorka, Daniel A Fitzgerald, Harriet de Wit, K Luan Phan

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: a randomized trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  5. Trial
  6. Cannabinoid Modulation of Frontolimbic Activation and Connectivity During Volitional Regulation of Negative Affect.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  7. Article
  8. Article
  9. Combinatorial approaches for treating neuropsychiatric social impairment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Effects of ∆BMC psychiatry · 2020
    Review
  14. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Neuroimaging of Fear-Associated Learning.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Stephanie M GorkaDepartment of Psychiatry (Gorka and Fitzgerald, and Prof and Dr Phan), and Department of Psychology, University of Illinois, Chicago, IL (Gorka and Prof and Dr Phan); Jesse Brown VA Medical Center, Mental Health Service Line, Chicago, IL (Fitzgerald and Prof and Dr Phan); University of Chicago, Department of Psychiatry and Behavioral Neurosciences, Chicago, IL (Prof de Wit); University of Illinois, Chicago Anatomy and Cell Biology, Chicago, IL (Prof and Dr Phan).
Daniel A FitzgeraldDepartment of Psychiatry (Gorka and Fitzgerald, and Prof and Dr Phan), and Department of Psychology, University of Illinois, Chicago, IL (Gorka and Prof and Dr Phan); Jesse Brown VA Medical Center, Mental Health Service Line, Chicago, IL (Fitzgerald and Prof and Dr Phan); University of Chicago, Department of Psychiatry and Behavioral Neurosciences, Chicago, IL (Prof de Wit); University of Illinois, Chicago Anatomy and Cell Biology, Chicago, IL (Prof and Dr Phan).
Harriet de WitDepartment of Psychiatry (Gorka and Fitzgerald, and Prof and Dr Phan), and Department of Psychology, University of Illinois, Chicago, IL (Gorka and Prof and Dr Phan); Jesse Brown VA Medical Center, Mental Health Service Line, Chicago, IL (Fitzgerald and Prof and Dr Phan); University of Chicago, Department of Psychiatry and Behavioral Neurosciences, Chicago, IL (Prof de Wit); University of Illinois, Chicago Anatomy and Cell Biology, Chicago, IL (Prof and Dr Phan).
K Luan PhanDepartment of Psychiatry (Gorka and Fitzgerald, and Prof and Dr Phan), and Department of Psychology, University of Illinois, Chicago, IL (Gorka and Prof and Dr Phan); Jesse Brown VA Medical Center, Mental Health Service Line, Chicago, IL (Fitzgerald and Prof and Dr Phan); University of Chicago, Department of Psychiatry and Behavioral Neurosciences, Chicago, IL (Prof de Wit); University of Illinois, Chicago Anatomy and Cell Biology, Chicago, IL (Prof and Dr Phan). klphan@uic.edu.
University of Chicago · USJesse Brown VA Medical Center · USUniversity of Illinois Chicago · US

Funding

Determinants of Drug Preference in Humans--Administrative SupplementR01DA002812 · NIDA · UNIVERSITY OF CHICAGO · PI DE WIT, HARRIET · 1985 to 2024
$10.6M
REINSTATEMENT OF DRUG TAKINGR01DA009133 · NIDA · UNIVERSITY OF CHICAGO · PI DE WIT, HARRIET · 1996 to 2009
$2.5M
Neuro-Genetic Markers SSRI Treatment Social AnxietyK23MH076198 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PHAN, K. LUAN · 2006 to 2010
$754k
Functional Neuroimaging of Opioid Effects on Affective ExperienceR03DA024197 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PHAN, KINH LUAN · 2007 to 2007
$228k
NIDA NIH HHS DA002812NIDA NIH HHS DA009133NIDA NIH HHS DA024197NIDA NIH HHS R01 DA002812NIDA NIH HHS R01 DA009133NIDA NIH HHS R03 DA024197NIMH NIH HHS K23 MH076198NIMH NIH HHS MH076198
6 · The paper itself

Abstract

backgroundΔ(9)-Tetrahydrocannabinol has been shown to modulate anxiety and facilitate the extinction of fear by inhibiting amygdala reactivity. Since functional coupling between the amygdala and prefrontal cortex is implicated in affective processes, it is possible that Δ(9)-tetrahydrocannabinol affects amygdala-prefrontal cortex functional connectivity in ways that differ across amygdala subregions: basolateral, centromedial, and superficial.

methodsThe aim of the study was to examine the effects of Δ(9)-tetrahydrocannabinol on functional connectivity between amygdala subregions and the prefrontal cortex during socio-emotional threat in healthy adults using a double-blind, placebo-controlled, within-subjects design. Sixteen subjects completed a functional magnetic resonance imaging task designed to probe amygdala responses to social threat. Amygdala subregion-prefrontal cortex functional connectivity was compared between Δ(9)-tetrahydrocannabinol and placebo using generalized psychophysiological interaction analyses.

resultsFindings indicated that Δ(9)-tetrahydrocannabinol enhanced basolateral and superficial amygdala connectivity to the rostral anterior cingulate/medial prefrontal cortex.

conclusionThese effects, including Δ(9)-tetrahydrocannabinol's potential ability to reduce threat perception or enhance socio-emotional regulation, may help understand the neurocircuitry of affect.

Indexed as

Facial ExpressionAdolescentAdultAmygdalaDouble-Blind MethodDronabinolFearFemaleFunctional LateralityHealthy VolunteersHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleNerve NetNeural PathwaysDronabinolOxygenPsychotropic Drugscannabisfunctional connectivitysocial threatΔ9-tetrahydrocannabinol

Identifiers

PMID25548107
PMCPMC4360235
OpenAlexW2161879251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.